The litigation, initiated by the City of Ann Arbor Retiree Health Care Benefit Plan & Trust, centers on claims that Zoetis obscured significant headwinds facing its core portfolio. According to the complaint, the company allegedly downplayed weakening prescription growth for Librela, a canine pain treatment, following FDA warnings concerning neurological risks. Furthermore, the suit contends that market share for key preventatives and dermatological treatments, including Simparica Trio, Apoquel, and Cytopoint, eroded due to aggressive lower-priced competition.

The impact of these undisclosed pressures became clear on May 7, 2026, when Zoetis released first-quarter financial results that triggered a 21.5% plunge in its stock price. Investors who acquired securities during the specified class period now have until July 27, 2026, to apply for lead plaintiff status. The law firm Kessler Topaz Meltzer & Check, LLP is currently coordinating with affected shareholders to discuss recovery options and the legal implications of the ongoing proceedings.